Baxalta Inc

Baxalta — Merger or Acquisition (January 2016)

31 slides from Baxalta's merger presentation, Jan 12, 2016

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements Forward-Looking Statements Statements included herein that are not historical facts, including without limitation statements concerning our proposed business combination with Baxalta Incorporated (“Baxalta”) and the timing and financial and strategic benefits thereof, our

  2. Slide 2: Forward Looking Statements: Additional Information

    Forward Looking Statements Additional Information This communication does not constitute an offer to buy or solicitation of any offer to sell securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. This communication relates to the

  3. Slide 3: Global Leader in Rare Diseases with Compelling Strategic/Financial Rationale

    Global Leader in Rare Diseases with Compelling Strategic/Financial Rationale $1B+ 65% >50 Multiple $1B+ durable, best-in-class franchises Revenue from rare diseases Rare disease pipeline programs >$500M + 16-17% Operating cost synergies alone Additional revenue synergies Attractive non-GAAP effectiv

  4. Slide 4: Proposed Transaction with Baxalta Would Add New Areas of Category Leadership

    Proposed Transaction with Baxalta Would Add 3 New Areas of Category Leadership Shire Baxalta 5 (1) Pending completion of Dyax acquisition (2) Subject to regulatory approvals. Source: Analyst consensus and Shire management projections. Category and 2015E net salesKey brands Oncology Immunology (~$2.5

  5. Slide 5: Double-digit Top-line Growth and Increasing Focus on Rare Diseases

    Double-digit Top-line Growth and Increasing Focus on Rare Diseases of revenue from rare diseases >$20B Rare diseases Shire Baxalta 2015E(1) Combined 2020E(2) Shire Combined 2015E(1) 6 Baxalta 2015E(1) (1) Based on Shire and Baxalta company guidance. (2) Based on Shire management projections. ~11% CA

  6. Slide 6: Combined Robust and Innovative Rare Disease Pipeline

    Combined Robust and Innovative Rare Disease Pipeline Preclinical Phase 2 Phase 3(3) SHP620(1) (Maribavir) CMV in transplant patients Registration Phase 1 SHP607 Prevention of ROP Firazyr (Japan) HAE NATPAR (EU) Hypoparathyroidism SHP606 (Lifitegrast) Dry eye disease SHP 621 (Meritage) EoE SHP610 San

  7. Slide 7: Developing and Sustaining Category Leadership

    Developing and Sustaining Category Leadership

  8. Slide 8: Shire: Industry-leading Rare Disease Capabilities with an Unparalleled Potential for Growth

    Shire: Industry-leading Rare Disease Capabilities with an Unparalleled Potential for Growth Cutting-edge flexible manufacturing Specialized research and development expertise Targeted, high-touch go-to-market model Category leadership in rare and specialty conditions Global commercial infrastructure

  9. Slide 9: Shire's Current Areas of Category Leadership

    Shire’s Current 5 Areas of Category Leadership 10 1 Pending completion of Dyax transaction Major marketed products Selected late-stage pipeline programs DX-29301 (HAE prophylaxis) SHP609 (Hunter intrathecal) SHP465 (ADHD) Lifitegrast (DED)SHP640 (Conjunctivitis) SHP607 (ROP) SHP621 (EOE) SHP625 (PFI

  10. Slide 10: Category Leadership: Ophthalmics

    Category Leadership: Ophthalmics Preclinical Phase 1 Phase 2 Phase 3 Registration Dry Eye Disease (lifitegrast) Bacterial and Viral Infectious Conjunctivitis (SHP640) Retinopathy of Prematurity (SHP607) adRP1 (SHP630) Glaucoma (SHP639) 11 1. Autosomal dominant retinitis pigmentosa

  11. Slide 11: Dry-Eye Disease (DED): A Complex Ocular Surface Condition

    Dry-Eye Disease (DED): A Complex Ocular Surface Condition • A chronic and progressive multifactorial disease of the tears and ocular surface • Associated with inflammation that may eventually lead to damage to the surface of the eye • Often diagnosed by patient reported symptoms (stinging, burning,

  12. Slide 12: DED: One of the Most Common Eye Diseases in the U.S.

    DED: One of the Most Common Eye Diseases in the U.S.1 ~29 million affected Incidence may be growing: aging population, menopause, use of other irritating medications, improved awareness/diagnosis 14 million diagnosed2 ~1/3 of diabetics may have DED3 7-8 million moderate/ patients2 severe Rx treatmen

  13. Slide 13: Lifitegrast: Specifically Designed to Address DED Inflammation

    Lifitegrast: Specifically Designed to Address DED Inflammation Small-molecule selected from 1500 candidate molecules Built specifically to block LFA-1 / ICAM-1 interaction ICAM-1 has been shown to be expressed at higher levels in patients with dry eye Acts as an ICAM-1 decoy and selectively binds wi

  14. Slide 14: Lifitegrast: Potential to be 1st Treatment Indicated for Signs AND Symptoms

    Lifitegrast: Potential to be 1st Treatment Indicated for Signs AND Symptoms1 Comprehensive clinical program conducted in ~2,000 patients OPUS-3 also met secondary endpoint of statistically significant impact on Symptoms after 14 days of treatment 1 2 Subject to approval by regulatory authorities OPU

  15. Slide 15: Lifitegrast: Next Steps in 2016

    Lifitegrast: Next Steps in 2016 Q3: 2016 • Potential approval and launch Q1: 2016 • Resubmission in response to FDA’s complete letter response Build-out commercial infrastructure Implement disease awareness campaign Continue engagement with international regulatory authorities Note: Subject to appro

  16. Slide 16: SHP607: Retinopathy of Prematurity (ROP)

    SHP607: Retinopathy of Prematurity (ROP) Mature Healthy Retina2 (Birth at 40 Weeks) • ROP is caused by abnormal blood vessel growth in the retina that can lead to retinal detachment and blindness ROP primarily affects premature babies, is one of the most common causes of visual loss in childhood, an

  17. Slide 17: SHP607 (IGF-1/IGF-1 BP) Replaces Low Levels of Intra-Uterine IGF-1

    SHP607 (IGF-1/IGF-1 BP) Replaces Low Levels of Intra-Uterine IGF-1 • Low levels of intra-uterine Insulin Like Growth Factor-1 (IGF-1) correlate with higher rates of ROP • IV infusions of SHP607 beginning w/in the first 24-48 hours of life replaces low levels of IGF-1 until endogenous production of I

  18. Slide 18: SHP607: Phase 2 Top-Line Data Expected in Q2 2016

    SHP607: Phase 2 Top-Line Data Expected in Q2 2016 Q2: 2016 Phase 2 top-line results Q1: 2016 Phase 2 fully enrolled Primary Endpoint: Prevention Secondary Endpoints: of ROP • • • • Incidence of Bronchopulmonary Dysplasia (BPD) Time to NICU discharge Brain volume 19 Growth

  19. Slide 19: Category Leadership: Hereditary Angioedema

    Category Leadership: Hereditary Angioedema SHP616 (CINRYZE SC) HAE Prophylaxis DX-2930 DX-29301 Novel antibody therapy Less frequent subcutaneous administration Very high efficacy in early trials Phase 3 development Cinryze and Firazyr Ability to address both prophylactic (Cinryze) and acute (Firazy

  20. Slide 20: DX-2930 Phase 1b Trial: Key Efficacy and Safety Data

    DX-2930 Phase 1b Trial: Key Efficacy and Safety Data • Phase 1b study in HAE patients who reported having at least 2 HAE attacks in the 3 months prior to study entry • Pre-specified, primary efficacy interval of 6 weeks • HAE attack rate was 0 in the 300 mg group and 0.045 attacks per week in the 40

  21. Slide 21: Category Leadership: Neuroscience / ADHD

    Category Leadership: Neuroscience / ADHD SHP465 Adult ADHD Adderall XR Pioneering stimulant treatment for ADHD AXR enabled true once-daily dosing Continues to be highly successful Vyvanse Leading branded treatment for pediatric and adult ADHD Became first and only licensed treatment for binge eating

  22. Slide 22: Category Leadership: GI / Endocrine – SHP621 for EoE

    Category Leadership: GI / Endocrine – SHP621 for EoE • • • • Eosinophilic Esophagitis (EoE): chronic immune-mediated condition with est. >150k patients in the US SHP621: Oral budenoside formulated in a viscous suspension 12-week, 93-patient Phase 2 trial1 met all endpoints Phase 3 trial underway 23

  23. Slide 23: Category Leadership: GI / Endocrine – SHP621 for EoE

    Category Leadership: GI / Endocrine — SHP621 for EoE * Eosinophilic Esophagitis (EoE): chronic immune-mediated condition with est. >150k patients in the US * SHP621: Oral budenoside formulated in a viscous suspension * 12-week, 93-patient Phase 2 trial’ met all endpoints + Phase 3 trial underway Co-

  24. Slide 24: Key Clinical Data and Regulatory Milestones in 2016

    Key Clinical Data and Regulatory Milestones in 2016 Clinical trial results SHP610 Firazyr HAE Japan Top-line data Regulatory filing or anticipated approval SanFilippo A Disease Phase 2 data Q1 Q2 Q3 Q4 SHP607 Lifitegrast Lifitegrast Retinopathy of Prematurity Phase 2 data Adult Dry Eye Disease FDA r

  25. Slide 25: 2016: A Year of Growth and Investment for Shire

    2016: A Year of Growth and Investment for Shire Expected return to double-digit topline growth rates Baxalta1 Integrate Advance SHP607 (ROP), DX-29303 (HAE) and SHP465 (ADHD) Expand and Launch lifitegrast2 Largest-ever number of Phase 3 trials (>12) strengthen manufacturing 1 Pending completion of B

  26. Slide 26: Our purpose

    LShire Our purpose We enable people with life-altering conditions to lead better lives.

  27. Slide 27: Our purpose

    Our purpose - We enable people with life-altering conditions to lead better lives. CShire

  28. Slide 28: The Shire/Baxalta Combination Will Not Cause the Spin-off of Baxalta by Baxter to be Taxable

    The Shire/Baxalta Combination Will Not Cause the Spin-off of Baxalta by Baxter to be Taxable • • The spin-off of Baxalta stock by Baxter (“Spin-off”) was designed to be tax-free Shire has been advised by Cravath, Swaine & Moore LLP that the Shire/Baxalta combination (“Combination”) will not cause th

  29. Slide 29: Continued Growth and Innovation in the Hemophilia Market

    Continued Growth and Innovation in the Hemophilia Market Global Hemophilia Market Revenues(1) ($M) 11,033 10,494 9,970 9,440 8,954 8,549 Segment growth driven by innovation and global reach Increasing diagnosis rates, esp. in developing countries Increasing adoption of prophylaxis, currently 25-30%(

  30. Slide 30: Breadth, Established Position, and Innovation Propel Immunoglobulins (IG) Business

    Breadth, Established Position, and Innovation Propel Immunoglobulins (IG) Business Baxalta’s Broad IG Portfolio The Only Once-A-Month IGSC Future Flagship Brand Expanding Baxalta’s IGSC Platform With 20% Concentration Baxalta’s Cornerstone IG brand The Only IgA < 1μg/ml Baxalta’s Platform for Growth

  31. Slide 31: Baxalta's Broad IG Portfolio

    Baxalta’s Broad IG Portfolio anding Baxalta’> The Only Baxalta's Cornerstone IGSC Platform With Once-A-Month IGSC G brand Future Flagship Brand HyQvia mena Globulin Infusion (Human) 1% with Recombinant Human Hyaluroniase mrmune Globulin intravenous (Human) ‘Salvert/Detergent Treated IgA bees than 1

Baxalta — Merger or Acquisition (January 2016) on 6ix